Summary

The vascular access device market is projected to reach USD 8.68 billion by 2031 from USD 6.27 billion in 2026, at a CAGR of 6.7% from 2026 to 2031. https://mnmimg.marketsandmarkets.com/Images/vascular-access-device-market1-img-overview.webp The vascular access device market is expanding due to the rise in chronic diseases such as cancer, heart disorders, and kidney failure, all of which require intravenous therapies. The increase in hospitalizations, surgical procedures, and the demand for critical care and emergency services is driving the need for these devices. Additionally, advancements in technology—such as safety-engineered devices, antimicrobial coatings, and ultrasound-guided placement—are enhancing clinical outcomes, reducing complications, and supporting broader adoption of vascular access devices. Besides, the growing elderly population, rising ambulatory care and home healthcare facilities, and the tremendous emphasis on infection control and patient safety are all driving the demand for vascular access devices in the healthcare system. “Based on type, the peripheral vascular access device segment is expected to experience the highest CAGR during the forecast period.” By type, the peripheral vascular access device segment is estimated to lead the vascular access device market because of the increasing need for short-term intravenous therapy in hospitals and other medical facilities. The demand for peripheral vascular access devices has been further propelled by the rise in chronic diseases, surgical and emergency procedures, and increased use of IV medications and fluids. Apart from these benefits, the devices are also preferred for their insertion convenience, cost, and lower risk of severe complications than central access. Moreover, new catheter materials, engineered safety designs that avoid needlestick injury, and a movement toward outpatient and more affordable care models are also contributing to the market's growth. “Based on application, the drug administration segment is projected to register the highest CAGR during the forecast period.” By application, the drug administration segment is projected to grow at the highest rate due to the increasing use of intravenous therapies in the treatment of chronic illnesses like cancer, heart diseases, infections, and autoimmune disorders. Demand is additionally supported by increasing dependence on IV drug delivery for chemotherapy, antibiotics, biologics, and pain management, owing to its rapid onset and higher bioavailability. Besides, the increase in hospital admissions, the extension of outpatient infusion centers, and home-based IV therapy are all contributing to the segment’s growth. The innovative features of vascular access devices, such as better dosing accuracy, lower infection risks, and long-term drug delivery support, are all contributing to their adoption in healthcare settings. “Based on end user, the clinic & ambulatory care centers segment is expected to grow at the highest rate during the forecast period.” The rise of clinics and ambulatory care centers has been a major factor in the growth of the vascular access device market, mainly driven by the trend of hospitals moving patients to outpatient care, which, in turn, is expected to cut down on overall healthcare costs. Besides, the scale-up of minimally invasive procedures, infusion therapies, chronic disease management, and same-day surgeries has contributed to the need for efficient and safe vascular access in these environments. Access to easy-to-use, low-complication vascular access devices is a major factor behind the rapid adoption by clinics and ASCs. Also, favorable reimbursement systems, patient preference for shorter recovery times, and the growth of stand-alone specialty clinics are some of the reasons further contributing to the market expansion. “Asia Pacific is estimated to register the highest CAGR during the forecast period.” The growth of outpatient services and facilities has significantly boosted the vascular access device market. Hospitals and patients are increasingly shifting their preference from inpatient to outpatient services due to the cost savings and reduced inconvenience associated with outpatient care. The rising use of vascular access devices for small surgeries, infusion therapies, chemotherapy administration, and chronic disease management has also contributed to market growth. Additionally, advancements in technology have enabled the quick, sterile, and straightforward insertion of these devices, further enhancing their appeal. Other favorable factors for the use of vascular access devices in clinics and ambulatory care centers include supportive reimbursement policies, quick procedure turnaround times, and patients' growing preference for same-day treatments. Key players in the vascular access device market Some of the major players in this market are Becton, Dickinson and Company (US), Teleflex Incorporated (US), ICU Medical, Inc. (US), B. Braun SE (Germany), AngioDynamics, Inc. (US), Medtronic, Plc (Ireland), Merit Medical Systems Inc. (US), Terumo Corporation (Japan), Nipro (Japan), Vygon (France), AMECATH (Egypt), Medical Components, Inc. (US), HealthLine Medical Products (US), Cook Medical (US), and Access Vascular, Inc. (US). Research Coverage: The report analyzes the vascular access device market and aims to estimate its size and future growth potential based on various segments, such as angioplasty stents, endovascular aneurysm repair stent grafts, inferior cava filters, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. The report includes a product portfolio matrix of various vascular access devices available in the market. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies. Reasons to Buy the Report The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall vascular access device market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities. This report provides insights into the following pointers: • Analysis of key divers (Growing prevalence of lifestyle diseases, increasing number of chemotherapy procedures, growing use of vascular access devices in pediatric patients), restraints (High cost associated with placement and maintenance of vascular access device, product recalls and failures), challenges (Shortage of skilled professionals, risks associated with vascular access devices), and opportunities (Technological Advancements, growth in number of hospitals) • Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the vascular access device market. • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the vascular access device market • Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices, and end users. • Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the vascular access device market. • Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the vascular access device market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 41
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 42
2 EXECUTIVE SUMMARY 43
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 43
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 44
2.3 DISRUPTIVE TRENDS IN VASCULAR ACCESS DEVICE MARKET 45
2.4 HIGH GROWTH SEGMENTS 46
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 47
3 PREMIUM INSIGHTS 48
3.1 VASCULAR ACCESS DEVICE MARKET OVERVIEW 48
3.2 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY AND END USER 49
3.3 GEOGRAPHIC SNAPSHOT OF VASCULAR ACCESS DEVICE MARKET 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 51
4.2.1 DRIVERS 52
4.2.1.1 Rising global prevalence of chronic and lifestyle-related diseases 52
4.2.1.2 Rapid growth in the geriatric population and associated vascular disease burden 53
4.2.1.3 Favorable reimbursement scenario for vascular procedures 54
4.2.1.4 Increase in cancer incidence driving demand for vascular access devices in chemotherapy 55
4.2.2 RESTRAINTS 56
4.2.2.1 High costs of vascular access device placement and maintenance 56
4.2.2.2 Rising product failures and device recalls 56
4.2.3 OPPORTUNITIES 57
4.2.3.1 Technological innovation in vascular access devices 57
4.2.3.2 Growing adoption of midline catheters in clinical and outpatient settings 58
4.2.4 CHALLENGES 58
4.2.4.1 Clinical complications associated with vascular access devices 58
4.2.4.2 Shortage of skilled professionals for vascular access device placement and management 59
4.3 UNMET NEEDS AND WHITE SPACES 59
4.3.1 UNMET NEEDS IN VASCULAR ACCESS DEVICE MARKET 59
4.3.2 WHITE SPACE OPPORTUNITIES 60
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
4.4.1 INTERCONNECTED MARKETS 62
4.4.2 CROSS-SECTOR OPPORTUNITIES 63
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 67
5.1.3 BARGAINING POWER OF BUYERS 67
5.1.4 BARGAINING POWER OF SUPPLIERS 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC OUTLOOK 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS & FORECAST 68
5.2.3 TRENDS IN GLOBAL MEDICAL DEVICES INDUSTRY 69
5.2.4 TRENDS IN GLOBAL HEALTHCARE INDUSTRY 70
5.3 SUPPLY CHAIN ANALYSIS 70
5.4 VALUE CHAIN ANALYSIS 72
5.5 ECOSYSTEM ANALYSIS 74
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE TREND OF CENTRAL VENOUS ACCESS DEVICES,
BY TYPE (2023–2025) 75
5.6.2 AVERAGE SELLING PRICE TREND OF PERIPHERAL VASCULAR ACCESS DEVICES, BY TYPE (2023–2025) 76
5.6.3 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY APPLICATION (2023–2025) 77
5.6.4 AVERAGE SELLING PRICE TREND, BY REGION (2023–2025) 77
5.7 TRADE ANALYSIS 78
5.7.1 IMPORT DATA FOR HS CODE 9018.39 79
5.7.2 EXPORT DATA FOR HS CODE 9018.39 79
5.8 KEY CONFERENCES & EVENTS, 2026–2027 80
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
5.10 INVESTMENT & FUNDING SCENARIO 82
5.11 CASE STUDY ANALYSIS 83
 
5.12 IMPACT OF US TARIFFS–VASCULAR ACCESS DEVICE MARKET 85
5.12.1 INTRODUCTION 85
5.12.2 KEY TARIFF RATES 85
5.12.3 PRICE IMPACT ANALYSIS 86
5.12.4 IMPACT ON COUNTRIES/REGIONS 87
5.12.5 IMPACT ON END-USE INDUSTRIES 89
5.12.5.1 Hospitals 89
5.12.5.2 Clinics 89
5.12.5.3 Ambulatory care centers 89
5.12.5.4 Other end users 90
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91
6.1 KEY EMERGING TECHNOLOGIES 91
6.1.1 NEEDLE-FREE AND CLOSED IV SYSTEMS 91
6.1.2 ULTRASOUND-GUIDED AND TIP-NAVIGATION SYSTEMS 91
6.2 COMPLEMENTARY TECHNOLOGIES 92
6.2.1 VEIN VISUALIZATION SYSTEMS 92
6.2.2 INFUSION PUMPS AND FLOW CONTROL SYSTEMS 92
6.3 ADJACENT TECHNOLOGIES 92
6.3.1 ULTRASOUND SYSTEMS FOR VASCULAR ACCESS 92
6.4 TECHNOLOGY/PRODUCT ROADMAP 93
6.4.1 NEAR TERM (2025–2027) 93
6.4.2 MID TERM (2028–2030) 94
6.4.3 LONG TERM (2030+) 94
6.5 PATENT ANALYSIS 96
6.5.1 JURISDICTION & TOP APPLICANT ANALYSIS 97
6.6 FUTURE APPLICATIONS 99
6.6.1 HOME-BASED AND REMOTE INFUSION THERAPIES 99
6.6.2 SMART VASCULAR ACCESS DEVICES WITH SENSOR INTEGRATION 99
6.6.3 EXPANSION OF CRITICAL CARE AND EXTRACORPOREAL THERAPIES 100
6.6.4 ULTRASOUND-GUIDED AND ROBOTIC VASCULAR ACCESS PLACEMENT 100
6.6.5 ADVANCED ANTIMICROBIAL AND BIOCOMPATIBLE CATHETER TECHNOLOGIES 100
6.6.6 PRECISION MEDICINE AND SPECIALIZED DRUG DELIVERY APPLICATIONS 100
6.7 IMPACT OF AI/GENERATIVE AI ON VASCULAR ACCESS DEVICE MARKET 101
6.7.1 BEST PRACTICES IN VASCULAR ACCESS DEVICE MARKET 102
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN VASCULAR ACCESS DEVICE MARKET 103
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 104
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN VASCULAR ACCESS DEVICE MARKET 105
7 REGULATORY LANDSCAPE & SUSTAINABILITY INITIATIVES 106
7.1 REGIONAL REGULATIONS & COMPLIANCE 106
7.1.1 REGULATORY ANALYSIS 106
7.1.1.1 North America 106
7.1.1.1.1 US 106
7.1.1.1.2 Canada 106
7.1.1.2 Europe 107
7.1.1.3 Asia Pacific 107
7.1.1.4 Latin America 108
7.1.1.5 Middle East & Africa 108
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
7.2 INDUSTRY STANDARDS 111
7.2.1 QUALITY MANAGEMENT SYSTEM FOR MEDICAL DEVICES (ISO 13485) 111
7.2.2 BIOLOGICAL EVALUATION OF MEDICAL DEVICES (ISO 10993) 111
7.2.3 INTRAVASCULAR CATHETERS (ISO 10555) 111
7.2.4 RISK MANAGEMENT FOR MEDICAL DEVICES (ISO 14971) 112
7.3 SUSTAINABILITY INITIATIVES 112
7.3.1 ENVIRONMENTAL SUSTAINABILITY IN VASCULAR ACCESS PRODUCT LIFECYCLE- BECTON, DICKINSON AND COMPANY 112
7.3.2 RESOURCE EFFICIENCY AND WASTE REDUCTION IN MEDICAL DEVICE MANUFACTURING – VYGON 112
7.3.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 113
7.3.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 114
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 116
8.1 DECISION-MAKING PROCESS 116
8.2 KEY BUYER STAKEHOLDERS AND THEIR EVALUATION CRITERIA 118
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 118
8.2.2 BUYING CRITERIA 119
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 121
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 122
8.5 MARKET PROFITABILITY 122
9 VASCULAR ACCESS DEVICE MARKET, BY TYPE 124
9.1 INTRODUCTION 125
9.2 CENTRAL VENOUS ACCESS DEVICES 125
9.2.1 PERIPHERALLY INSERTED CENTRAL CATHETERS 127
9.2.1.1 Enhanced convenience and risk reduction boost PICC adoption 127
9.2.2 TUNNELED CATHETERS 128
9.2.2.1 Advantages of tunneled catheters, such as lower risk of infection and lower chances of accidental removal, to boost demand 128
9.2.2.2 Volume analysis for tunneled cathers market, by region,
2024–2031 (Units) 130
9.2.3 NON-TUNNELED CATHETERS 130
9.2.3.1 Increasing adoption of non-tunneled CVCs driven by affordability and their critical role in emergency care 130
9.2.3.2 Volume analysis for non-tunneled cathers market, by region,
2024–2031 (Units) 132
9.2.4 IMPLANTABLE PORTS 132
9.2.4.1 Implantable conventional ports 134
9.2.4.1.1 Lowest risk of infection associated with implanted ports to support growth 134
9.2.4.2 Implantable power injectable ports 135
9.2.4.2.1 Increasing chemotherapy treatments and high-flow infusion needs fuel demand for implantable power injectable ports 135
9.3 PERIPHERAL VASCULAR ACCESS DEVICES 136
9.3.1 PERIPHERAL VENOUS ACCESS DEVICES 138
9.3.1.1 Peripheral intravenous catheters 140
9.3.1.1.1 Growing hospitalizations and widespread IV therapy drive demand for peripheral intravenous catheters in healthcare 140
9.3.1.2 Volume analysis for peripheral intravenous catheters market,
by region, 2024–2031 (Units) 141
9.3.1.3 Midline catheters 141
9.3.1.3.1 Cost-efficiency and extended treatment capabilities drive midline catheter growth in vascular access markets 141
9.3.1.3.2 MST max barrier midline catheters 143
9.3.1.3.3 Integrated/Accelerated midline catheters 144
9.3.1.4 Butterfly/Winged steel needles 146
9.3.1.4.1 Wide usage of winged steel needles in blood sampling and diagnosis to propel growth 146
9.3.2 PERIPHERAL ARTERIAL ACCESS DEVICES 148
9.3.2.1 Real-time hemodynamic monitoring in critical and surgical care to drive market 148
9.3.2.2 Volume analysis for peripheral arterial access devices market,
by region, 2024–2031 (Units) 150
9.4 ACCESSORIES 150
9.4.1 RECURRENT NEED FOR ACCESSORIES TO BOOST MARKET 150
9.5 INTRAOSSEOUS VASCULAR ACCESS DEVICES 152
9.5.1 INCREASING INCIDENCE OF CARDIAC ARRESTS TO DRIVE DEMAND FOR INTRAOSSEOUS VASCULAR ACCESS DEVICES 152
10 VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION 154
10.1 INTRODUCTION 155
10.2 INTRAVENOUS 155
10.2.1 GROWING HOSPITALIZATIONS AND DEMAND FOR FAST THERAPEUTIC EFFECTS DRIVE USAGE OF INTRAVENOUS ROUTE 155
 
10.3 SUBCUTANEOUS 157
10.3.1 RISING CANCER CASES AND DEMAND FOR LONG-TERM THERAPIES DRIVE SEGMENTAL GROWTH 157
10.4 INTRAOSSEOUS 158
10.4.1 RISING PREVALENCE OF CORONARY ARTERY DISEASES TO DRIVE MARKET GROWTH 158
11 VASCULAR ACCESS DEVICE MARKET, BY APPLICATION 160
11.1 INTRODUCTION 161
11.2 DRUG ADMINISTRATION 161
11.2.1 CHEMOTHERAPY 163
11.2.1.1 Rising cancer cases to propel chemotherapy demand and boost market growth 163
11.2.2 OTHER DRUG ADMINISTRATION APPLICATIONS 164
11.3 FLUID & NUTRITION ADMINISTRATION 165
11.3.1 GROWING USE OF PERIPHERAL VASCULAR ACCESS DEVICES FOR SHORT-TERM NUTRITIONAL THERAPY TO SUPPORT MARKET 165
11.4 BLOOD TRANSFUSION 167
11.4.1 FREQUENT NEED FOR BLOOD TRANSFUSION IN THE TREATMENT OF VARIOUS CONDITIONS TO BOOST GROWTH 167
11.5 DIAGNOSTICS & TESTING 168
11.5.1 GROWING POPULARITY OF PERIPHERAL LINES FOR DIAGNOSTIC & TESTING APPLICATIONS TO DRIVE MARKET GROWTH 168
12 VASCULAR ACCESS DEVICE MARKET, BY END USER 170
12.1 INTRODUCTION 171
12.2 HOSPITALS 171
12.2.1 PUBLIC HOSPITALS 173
12.2.1.1 Affordability and accessibility drive patients toward public hospitals 173
12.2.2 PRIVATE HOSPITALS 174
12.2.2.1 Rising availability of specialized treatments and diagnostic services in private hospitals fuels growth 174
12.3 CLINICS 175
12.3.1 INCREASING DEMAND FOR OUTPATIENT PROCEDURES AND COST-EFFECTIVE TREATMENTS TO PROPEL MARKET 175
12.4 AMBULATORY CARE CENTERS 177
12.4.1 INCREASING DEMAND FOR OUTPATIENT PROCEDURES AND COST-EFFECTIVE TREATMENTS TO SUPPORT MARKET GROWTH 177
12.5 OTHER END USERS 178
 
13 VASCULAR ACCESS DEVICE MARKET, BY REGION 180
13.1 INTRODUCTION 181
13.2 NORTH AMERICA 181
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 181
13.2.2 NORTH AMERICA VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 184
13.2.3 NORTH AMERICA VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 185
13.2.4 US 188
13.2.4.1 US to dominate North American vascular access device market during forecast period 188
13.2.5 CANADA 192
13.2.5.1 Rising cancer prevalence and advanced research initiatives propel Canada's vascular access device market growth. 192
13.3 EUROPE 197
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 197
13.3.2 EUROPE VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 199
13.3.3 EUROPE VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 200
13.3.4 GERMANY 203
13.3.4.1 Germany to dominate European vascular access device market during forecast period 203
13.3.5 UK 207
13.3.5.1 Increased need for intravenous treatments due to CKD and CHD drives market growth 207
13.3.6 FRANCE 212
13.3.6.1 Growing elderly population and healthcare needs foster rapid market growth for vascular access devices in France 212
13.3.7 ITALY 216
13.3.7.1 Strong healthcare policies by government to propel growth 216
13.3.8 SPAIN 221
13.3.8.1 Growing geriatric population to increase demand for vascular access devices 221
13.3.9 REST OF EUROPE 225
13.4 ASIA PACIFIC 229
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 229
13.4.2 ASIA PACIFIC: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 232
13.4.3 ASIA PACIFIC: VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 233
13.4.4 CHINA 236
13.4.4.1 China to dominate Asia Pacific’s vascular access device market during forecast period. 236
 
13.4.5 INDIA 241
13.4.5.1 Increasing healthcare expenditure and chronic disease prevalence support market growth in India 241
13.4.6 JAPAN 245
13.4.6.1 Growing healthcare needs among elderly individuals fuel vascular access device market expansion in Japan. 245
13.4.7 AUSTRALIA 250
13.4.7.1 Rising demand for pharmaceuticals and increasing advancements in drug formulations to drive market 250
13.4.8 SOUTH KOREA 254
13.4.8.1 Increasing diabetes and CKD prevalence to drive the market growth 254
13.4.9 REST OF ASIA PACIFIC 259
13.5 LATIN AMERICA 263
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 263
13.5.2 LATIN AMERICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 265
13.5.3 LATIN AMERICA: VOLUME ANALYSIS FOR PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE (UNITS) 266
13.5.4 BRAZIL 269
13.5.4.1 Expanding chronic disease prevalence in Brazil supports demand growth 269
13.5.5 MEXICO 274
13.5.5.1 Growing ESRD cases and obesity trends to propel market growth 274
13.5.6 REST OF LATIN AMERICA 278
13.6 MIDDLE EAST & AFRICA 283
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 283
13.6.2 MIDDLE EAST & AFRICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 285
13.6.3 MIDDLE EAST & AFRICA: VOLUME ANALYSIS FOR CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE (UNITS) 286
13.6.4 GCC COUNTRIES 289
13.6.4.1 Kingdom of Saudi Arabia 293
13.6.4.1.1 Rising chronic disease burden and strategic healthcare investments to drive market 293
13.6.4.2 United Arab Emirates 298
13.6.4.2.1 Healthcare infrastructural development and rising medical tourism to drive demand 298
13.6.4.3 Rest of GCC Countries 302
13.6.5 REST OF MIDDLE EAST & AFRICA 306
 
14 COMPETITIVE LANDSCAPE 311
14.1 INTRODUCTION 311
14.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2024–2026 311
14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VASCULAR ACCESS DEVICE MARKET 312
14.3 REVENUE ANALYSIS, 2023–2025 314
14.4 MARKET SHARE ANALYSIS, 2025 315
14.4.1 GLOBAL MARKET SHARE ANALYSIS (2025) 315
14.4.2 US MARKET SHARE ANALYSIS (2025) 317
14.4.3 EUROPE MARKET SHARE ANALYSIS (2025) 318
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 319
14.5.1 STARS 319
14.5.2 EMERGING LEADERS 319
14.5.3 PERVASIVE PLAYERS 319
14.5.4 PARTICIPANTS 319
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 321
14.5.5.1 Company footprint 321
14.5.5.2 Type footprint 322
14.5.5.3 Route of insertion footprint 322
14.5.5.4 Application footprint 323
14.5.5.5 Region footprint 324
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 325
14.6.1 PROGRESSIVE COMPANIES 325
14.6.2 RESPONSIVE COMPANIES 325
14.6.3 DYNAMIC COMPANIES 325
14.6.4 STARTING BLOCKS 325
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 327
14.6.5.1 Detailed list of key startups/SMEs 327
14.6.5.2 Competitive benchmarking of key startups/SMEs 328
14.7 COMPANY VALUATION AND FINANCIAL METRICS 329
14.7.1 FINANCIAL METRICS 329
14.7.2 COMPANY VALUATION 329
14.8 BRAND/PRODUCT COMPARISON 330
14.9 COMPETITIVE SCENARIO 331
14.9.1 PRODUCT LAUNCHES & APPROVALS 331
14.9.2 DEALS 332
14.9.3 EXPANSIONS 333
14.9.4 OTHER DEVELOPMENTS 335
 
15 COMPANY PROFILES 336
15.1 KEY PLAYERS 336
15.1.1 BECTON, DICKINSON AND COMPANY 336
15.1.1.1 Business overview 336
15.1.1.2 Products offered 337
15.1.1.3 Recent developments 343
15.1.1.3.1 Product launches & approvals 343
15.1.1.3.2 Other developments 343
15.1.1.4 MnM view 344
15.1.1.4.1 Right to win 344
15.1.1.4.2 Strategic choices 344
15.1.1.4.3 Weaknesses & competitive threats 344
15.1.2 TERUMO CORPORATION 345
15.1.2.1 Business overview 345
15.1.2.2 Products offered 346
15.1.2.3 Recent developments 347
15.1.2.3.1 Product launches & approvals 347
15.1.2.3.2 Expansions 348
15.1.2.3.3 Other developments 348
15.1.3 TELEFLEX INCORPORATED 349
15.1.3.1 Business overview 349
15.1.3.2 Products offered 350
15.1.3.3 Recent developments 352
15.1.3.3.1 Product launches & approvals 352
15.1.3.3.2 Deals 353
15.1.3.3.3 Other developments 353
15.1.3.4 MnM view 354
15.1.3.4.1 Right to win 354
15.1.3.4.2 Strategic choices 354
15.1.3.4.3 Weaknesses & competitive threats 354
15.1.4 ICU MEDICAL INC. 355
15.1.4.1 Business overview 355
15.1.4.2 Products offered 356
15.1.4.3 Recent developments 359
15.1.4.3.1 Product launches & approvals 359
15.1.4.3.2 Expansions 360
15.1.4.3.3 Other developments 360
15.1.4.4 MnM view 360
15.1.4.4.1 Right to win 360
15.1.4.4.2 Strategic choices 361
15.1.4.4.3 Weaknesses & competitive threats 361
 
15.1.5 B. BRAUN SE 362
15.1.5.1 Business overview 362
15.1.5.2 Products offered 363
15.1.5.3 Recent developments 368
15.1.5.3.1 Product launches & approvals 368
15.1.5.3.2 Other developments 369
15.1.5.4 MnM view 369
15.1.5.4.1 Right to win 369
15.1.5.4.2 Strategic choices 369
15.1.5.4.3 Weaknesses and competitive threats 369
15.1.6 MERIT MEDICAL SYSTEMS 370
15.1.6.1 Business overview 370
15.1.6.2 Products offered 371
15.1.6.3 Recent developments 373
15.1.6.3.1 Product launches 373
15.1.6.3.2 Deals 374
15.1.6.3.3 Other developments 374
15.1.7 NIPRO CORPORATION 375
15.1.7.1 Business overview 375
15.1.7.2 Products offered 376
15.1.7.3 Recent developments 377
15.1.7.3.1 Deals 377
15.1.7.3.2 Expansions 377
15.1.7.3.3 Other developments 378
15.1.7.4 MnM view 378
15.1.7.4.1 Right to Win 378
15.1.7.4.2 Strategic choices 378
15.1.7.4.3 Weaknesses & competitive threats 379
15.1.8 VYGON 380
15.1.8.1 Business overview 380
15.1.8.2 Products offered 380
15.1.8.3 Recent developments 386
15.1.8.3.1 Deals 386
15.1.9 ANGIODYNAMICS 387
15.1.9.1 Business overview 387
15.1.9.2 Products offered 388
15.1.9.3 Recent developments 389
15.1.9.3.1 Product launches and approvals 389
 
15.1.10 MOZARC MEDICAL HOLDING LLC 390
15.1.10.1 Business overview 390
15.1.10.2 Products offered 390
15.1.10.3 Recent developments 391
15.1.10.3.1 Deals 391
15.1.10.3.2 Other developments 392
15.1.11 SPECTRUM VASCULAR 393
15.1.11.1 Business overview 393
15.1.11.2 Products offered 393
15.1.11.3 Recent developments 395
15.1.11.3.1 Deals 395
15.1.11.3.2 Expansions 396
15.1.12 AMECATH 397
15.1.12.1 Business overview 397
15.1.12.2 Products offered 397
15.1.13 MEDICAL COMPONENTS, INC. 400
15.1.13.1 Business overview 400
15.1.13.2 Products offered 400
15.1.13.3 Recent developments 402
15.1.13.3.1 Product launches and approvals 402
15.1.14 HEALTHLINE MEDICAL PRODUCTS 403
15.1.14.1 Business overview 403
15.1.14.2 Products offered 403
15.1.14.3 Recent developments 404
15.1.14.3.1 Deals 404
15.1.15 ACCESS VASCULAR, INC. 405
15.1.15.1 Business overview 405
15.1.15.2 Products offered 405
15.1.15.3 Recent developments 406
15.1.15.3.1 Product launches and approvals 406
15.1.15.3.2 Deals 406
15.1.15.3.3 Other developments 407
15.2 OTHER PLAYERS 408
15.2.1 ARGON MEDICAL DEVICES 408
15.2.2 PAKUMED MEDICAL PRODUCTS GMBH 409
15.2.3 GUANGDONG BAIHE MEDICAL TECHNOLOGY CO., LTD. 410
15.2.4 PFM MEDICAL GMBH 411
15.2.5 MEDI-TECH DEVICES PVT. LTD. 412
15.2.6 KIMAL 413
15.2.7 POLYMED 414
15.2.8 DELTA MED S.P.A. 415
15.2.9 NEWTECH MEDICAL DEVICES PVT. LTD. 416
15.2.10 SHANGHAI PUYI MEDICAL INSTRUMENTS CO., LTD. 417
16 RESEARCH METHODOLOGY 418
16.1 RESEARCH DATA 418
16.1.1 SECONDARY DATA 419
16.1.1.1 Key data from secondary sources 420
16.1.2 PRIMARY DATA 420
16.1.2.1 Key data from primary sources 422
16.1.2.2 Key industry insights 422
16.2 MARKET SIZE ESTIMATION 424
16.3 GROWTH FORECAST 428
16.4 MARKET BREAKDOWN & DATA TRIANGULATION 430
16.5 MARKET RANKING ANALYSIS 431
16.6 STUDY ASSUMPTIONS 431
16.7 RESEARCH LIMITATIONS 431
16.7.1 METHODOLOGY-RELATED LIMITATIONS 431
16.7.2 SCOPE-RELATED LIMITATIONS 432
16.8 RISK ASSESSMENT 432
17 APPENDIX 433
17.1 DISCUSSION GUIDE 433
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 441
17.3 CUSTOMIZATION OPTIONS 443
17.3.1 PRODUCT ANALYSIS 443
17.3.2 GEOGRAPHIC ANALYSIS 443
17.3.3 COMPANY INFORMATION 443
17.4 RELATED REPORTS 443
17.5 AUTHOR DETAILS 444

ページTOPに戻る

List of Tables/Graphs

TABLE 1 VASCULAR ACCESS DEVICE MARKET: INCLUSIONS & EXCLUSIONS 40
TABLE 2 STANDARD CURRENCY CONVERSION RATES 41
TABLE 3 DIABETES POPULATION, BY REGION, 2024 VS. 2050 52
TABLE 4 TOP 10 COUNTRIES WITH THE HIGHEST SMOKING RATE (2025) 53
TABLE 5 GERIATRIC POPULATION, BY REGION (2015-2030) 54
TABLE 6 US: REIMBURSEMENT FOR VASCULAR PROCEDURES (2026) 55
TABLE 7 VASCULAR ACCESS DEVICE MARKET: PORTER’S FIVE FORCES ANALYSIS 65
TABLE 8 GDP CHANGE, BY KEY COUNTRY, 2021–2030 (IN USD BILLION) 68
TABLE 9 AVERAGE SELLING PRICE TREND OF CENTRAL VENOUS ACCESS DEVICES, BY TYPE (2023–2025) (USD) 76
TABLE 10 AVERAGE SELLING PRICE TREND OF PERIPHERAL VASCULAR ACCESS DEVICES,
BY TYPE (2023−2025) (USD) 76
TABLE 11 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY APPLICATION (2023−2025) (USD) 77
TABLE 12 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION (2023−2025) (USD) 78
TABLE 13 IMPORT DATA FOR HS CODE 9018.39, BY COUNTRY,
2021–2025 (USD THOUSANDS) 79
TABLE 14 EXPORT DATA FOR HS CODE 9018.39, BY COUNTRY,
2021–2025 (USD THOUSANDS) 79
TABLE 15 VASCULAR ACCESS DEVICE MARKET: MAJOR CONFERENCES & EVENTS IN
2026-2027E 80
TABLE 16 CASE STUDY 1: IMPROVING VASCULAR ACCESS OUTCOMES THROUGH STANDARDIZED VASCULAR ACCESS MANAGEMENT 83
TABLE 17 CASE STUDY 2: REDUCING CATHETER-RELATED BLOODSTREAM INFECTIONS USING ANTIMICROBIAL CENTRAL VENOUS CATHETERS 84
TABLE 18 CASE STUDY 3: IMPROVING VASCULAR ACCESS EFFICIENCY THROUGH ULTRASONOGRAPHY-GUIDED CATHETER PLACEMENT 84
TABLE 19 US ADJUSTED RECIPROCAL TARIFF RATES 85
TABLE 20 US: IMPACT OF TARIFFS 87
TABLE 21 ASIA PACIFIC: IMPACT OF TARIFFS 87
TABLE 22 EUROPE: IMPACT OF TARIFFS 88
TABLE 23 VASCULAR ACCESS DEVICE MARKET: MAJOR PATENTS 98
TABLE 24 BEST PRACTICES IN VASCULAR ACCESS DEVICE MARKET 102
TABLE 25 BEST PRACTICES IN CASE STUDIES OF AI IMPLEMENTATION IN THE VASCULAR ACCESS DEVICE MARKET 103
TABLE 26 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS 104
TABLE 27 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
TABLE 28 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 109
TABLE 29 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
TABLE 30 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
TABLE 31 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 111
TABLE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VASCULAR ACCESS DEVICES 118
TABLE 33 KEY BUYING CRITERIA FOR VASCULAR ACCESS DEVICES, BY END USER 120
TABLE 34 VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 125
TABLE 35 CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 126
TABLE 36 CENTRAL VENOUS ACCESS DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 126
TABLE 37 PERIPHERALLY INSERTED CENTRAL CATHETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 38 TUNNELED PRODUCT CATHETER BY KEY PLAYERS (2025) 129
TABLE 39 TUNNELED CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 129
TABLE 40 TUNNELED CATHETERS MARKET VOLUME, BY REGION, 2024–2031 (UNITS) 130
TABLE 41 NON-TUNNELED PRODUCT CATHETER BY KEY PLAYERS (2025) 131
TABLE 42 NON-TUNNELED CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 43 NON-TUNNELED CATHETERS MARKET VOLUME, BY REGION, 2024–2031 (UNITS) 132
TABLE 44 IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 132
TABLE 45 IMPLANTABLE PORTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 46 IMPLANTABLE CONVENTIONAL PORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 134
TABLE 47 IMPLANTABLE POWER INJECTABLE PORTS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 135
TABLE 48 PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 136
TABLE 49 PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 137
TABLE 50 PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 138
TABLE 51 PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 139
TABLE 52 PERIPHERAL INTRAVENOUS CATHETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 140
TABLE 53 PERIPHERAL INTRAVENOUS CATHETERS MARKET VOLUME, BY REGION,
2024–2031 (UNITS) 141
TABLE 54 MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 142
TABLE 55 MIDLINE CATHETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 56 MIDLINE CATHETER-MAX BARRIER PRODUCT PORTFOLIO BY PRODUCT TYPE
AND COMPANY (2025) 143
TABLE 57 MST MAX BARRIER MIDLINE CATHETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 144
TABLE 58 MIDLINE CATHETER -INTEGRATED/ACCELERATED PRODUCT PORTFOLIO
BY PRODUCT TYPE AND COMPANY (2025) 145
TABLE 59 INTEGRATED/ACCELERATED MIDLINE CATHETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 145
TABLE 60 BUTTERFLY/WINGED STEEL NEEDLES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 147
TABLE 61 PERIPHERAL ARTERIAL CATHTER PRODUCT BY KEY PLAYERS (2025) 148
TABLE 62 PERIPHERAL ARTERIAL ACCESS DEVICES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 149
TABLE 63 PERIPHERAL ARTERIAL ACCESS DEVICES MARKET VOLUME, BY REGION,
2024–2031 (UNITS) 150
TABLE 64 VASCULAR ACCESS DEVICE ACCESSORIES MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 151
TABLE 65 INTRAOSSEOUS VASCULAR ACCESS DEVICE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 152
TABLE 66 VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 155
TABLE 67 VASCULAR ACCESS DEVICE MARKET FOR INTRAVENOUS ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 68 VASCULAR ACCESS DEVICE MARKET FOR SUBCUTANEOUS ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 69 VASCULAR ACCESS DEVICE MARKET FOR INTRAOSSEOUS ROUTE, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 70 VASCULAR ACCESS DEVICE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 161
TABLE 71 VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 162
TABLE 72 VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 73 VASCULAR ACCESS DEVICE MARKET FOR CHEMOTHERAPY, BY COUNTRY,
2024–2031 (USD MILLION) 163
TABLE 74 VASCULAR ACCESS DEVICE MARKET FOR OTHER DRUG ADMINISTRATION APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 75 VASCULAR ACCESS DEVICE MARKET FOR FLUID & NUTRITION ADMINISTRATION, BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 76 VASCULAR ACCESS DEVICE MARKET FOR BLOOD TRANSFUSION, BY COUNTRY, 2024–2031 (USD MILLION) 167
TABLE 77 VASCULAR ACCESS DEVICE MARKET FOR DIAGNOSTICS & TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 78 VASCULAR ACCESS DEVICE MARKET, BY END USER, 2024–2031 (USD MILLION) 171
TABLE 79 VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 172
TABLE 80 VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY COUNTRY,
2024–2031 (USD MILLION) 172
TABLE 81 VASCULAR ACCESS DEVICE MARKET FOR PUBLIC HOSPITALS, BY COUNTRY,
2024–2031 (USD MILLION) 173
TABLE 82 VASCULAR ACCESS DEVICE MARKET FOR PRIVATE HOSPITALS, BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 83 VASCULAR ACCESS DEVICE MARKET FOR CLINICS, BY COUNTRY,
2024–2031 (USD MILLION) 176
TABLE 84 VASCULAR ACCESS DEVICE MARKET FOR AMBULATORY CARE CENTERS,
BY COUNTRY, 2024–2031 (USD MILLION) 177
TABLE 85 VASCULAR ACCESS DEVICE MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 86 VASCULAR ACCESS DEVICE MARKET, BY REGION, 2024–2031 (USD MILLION) 181
TABLE 87 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 182
TABLE 88 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 183
TABLE 89 NORTH AMERICA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 183
TABLE 90 NORTH AMERICA VOLUME ANALYSIS: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 184
TABLE 91 NORTH AMERICA: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 184
TABLE 92 NORTH AMERICA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 184
TABLE 93 NORTH AMERICA VOLUME ANALYSIS : PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 185
TABLE 94 NORTH AMERICA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 185
TABLE 95 NORTH AMERICA: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 186
TABLE 96 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 186
TABLE 97 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 186
TABLE 98 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 99 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 187
TABLE 100 NORTH AMERICA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 187
TABLE 101 US: KEY MACROINDICATORS 188
TABLE 102 US: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 103 US: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 189
TABLE 104 US: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 189
TABLE 105 US: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 190
TABLE 106 US: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 190
TABLE 107 US: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 190
TABLE 108 US: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 191
TABLE 109 US: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 191
TABLE 110 US: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 111 US: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 192
TABLE 112 US: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 192
TABLE 113 CANADA: KEY MACROINDICATORS 193
TABLE 114 CANADA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 193
TABLE 115 CANADA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 193
TABLE 116 CANADA: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 117 CANADA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 194
TABLE 118 CANADA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 194
TABLE 119 CANADA: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 195
TABLE 120 CANADA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 195
TABLE 121 CANADA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 195
TABLE 122 CANADA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 196
TABLE 123 CANADA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 196
TABLE 124 CANADA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 196
TABLE 125 EUROPE: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 198
TABLE 126 EUROPE: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 198
TABLE 127 EUROPE: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 199
TABLE 128 EUROPE VOLUME ANALYSIS: CENTRAL VENOUS ACCESS DEVICES MARKET,
BY TYPE, 2024–2031 (THOUSAND UNITS) 199
TABLE 129 EUROPE: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 199
TABLE 130 EUROPE: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 200
TABLE 131 EUROPE VOLUME ANALYSIS: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 200
TABLE 132 EUROPE: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 201
TABLE 133 EUROPE: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 201
TABLE 134 EUROPE: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 201
TABLE 135 EUROPE: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 202
TABLE 136 EUROPE: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 202
TABLE 137 EUROPE: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 202
TABLE 138 EUROPE: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 203
TABLE 139 GERMANY: KEY MACROINDICATORS 203
TABLE 140 GERMANY: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 204
TABLE 141 GERMANY: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 204
TABLE 142 GERMANY: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 204
TABLE 143 GERMANY: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 205
TABLE 144 GERMANY: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 205
TABLE 145 GERMANY: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 205
TABLE 146 GERMANY: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 206
TABLE 147 GERMANY: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 206
TABLE 148 GERMANY: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 149 GERMANY: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 150 GERMANY: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 207
TABLE 151 UK: KEY MACROINDICATORS 208
TABLE 152 UK: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 208
TABLE 153 UK: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 209
TABLE 154 UK: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 209
TABLE 155 UK: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 209
TABLE 156 UK: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 210
TABLE 157 UK: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 210
TABLE 158 UK: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 210
TABLE 159 UK: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 211
TABLE 160 UK: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 161 UK: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 211
TABLE 162 UK: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 212
TABLE 163 FRANCE: KEY MACROINDICATORS 212
TABLE 164 FRANCE: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 213
TABLE 165 FRANCE: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 213
TABLE 166 FRANCE: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 167 FRANCE: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 214
TABLE 168 FRANCE: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 214
TABLE 169 FRANCE: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 214
TABLE 170 FRANCE: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 215
TABLE 171 FRANCE: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 215
TABLE 172 FRANCE: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 173 FRANCE: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 216
TABLE 174 FRANCE: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 216
TABLE 175 ITALY: KEY MACROINDICATORS 217
TABLE 176 ITALY: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 217
TABLE 177 ITALY: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 217
TABLE 178 ITALY: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 218
TABLE 179 ITALY: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 180 ITALY: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 218
TABLE 181 ITALY: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 182 ITALY: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 219
TABLE 183 ITALY: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 219
TABLE 184 ITALY: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 220
TABLE 185 ITALY: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 186 ITALY: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 220
TABLE 187 SPAIN: KEY MACROINDICATORS 221
TABLE 188 SPAIN: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 189 SPAIN: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 222
TABLE 190 SPAIN: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 191 SPAIN: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 222
TABLE 192 SPAIN: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 223
TABLE 193 SPAIN: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 194 SPAIN: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 223
TABLE 195 SPAIN: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 224
TABLE 196 SPAIN: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 224
TABLE 197 SPAIN: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 224
TABLE 198 SPAIN: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 225
TABLE 199 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 200 REST OF EUROPE: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 201 REST OF EUROPE: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 226
TABLE 202 REST OF EUROPE: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 203 REST OF EUROPE: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 204 REST OF EUROPE: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 227
TABLE 205 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 228
TABLE 206 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 228
TABLE 207 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 208 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 229
TABLE 209 REST OF EUROPE: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 210 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 211 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 231
TABLE 212 ASIA PACIFIC: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 232
TABLE 213 ASIA PACIFIC: VOLUME ANLYSIS CENTRAL VENOUS ACCESS DEVICES MARKET,
BY TYPE, 2024–2031 (THOUSAND UNITS) 232
TABLE 214 ASIA PACIFIC: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 232
TABLE 215 ASIA PACIFIC: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 233
TABLE 216 ASIA PACIFIC: VOLUME ANALYSIS PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 233
TABLE 217 ASIA PACIFIC: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 234
TABLE 218 ASIA PACIFIC: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 219 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 234
TABLE 220 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 235
TABLE 221 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 235
TABLE 222 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 235
TABLE 223 ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 224 CHINA: KEY MACROINDICATORS 237
TABLE 225 CHINA: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 226 CHINA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 237
TABLE 227 CHINA: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 228 CHINA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 238
TABLE 229 CHINA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 238
TABLE 230 CHINA: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 239
TABLE 231 CHINA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 239
TABLE 232 CHINA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 239
TABLE 233 CHINA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 234 CHINA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 240
TABLE 235 CHINA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 240
TABLE 236 INDIA: KEY MACROINDICATORS 241
TABLE 237 INDIA: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 238 INDIA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 242
TABLE 239 INDIA: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 240 INDIA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 241 INDIA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 243
TABLE 242 INDIA: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 243 INDIA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 244
TABLE 244 INDIA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 244
TABLE 245 INDIA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 246 INDIA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 245
TABLE 247 INDIA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 245
TABLE 248 JAPAN: KEY MACROINDICATORS 246
TABLE 249 JAPAN: VASCULAR ACCESS DEVICE MARKET, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 250 JAPAN: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 247
TABLE 251 JAPAN: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247
TABLE 252 JAPAN: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 247
TABLE 253 JAPAN: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 248
TABLE 254 JAPAN: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 255 JAPAN: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 248
TABLE 256 JAPAN: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 249
TABLE 257 JAPAN: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 249
TABLE 258 JAPAN: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 249
TABLE 259 JAPAN: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 250
TABLE 260 AUSTRALIA: KEY MACROINDICATORS 250
TABLE 261 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 262 AUSTRALIA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 251
TABLE 263 AUSTRALIA: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 251
TABLE 264 AUSTRALIA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 265 AUSTRALIA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 252
TABLE 266 AUSTRALIA: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 267 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 253
TABLE 268 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 253
TABLE 269 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 270 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 271 AUSTRALIA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 254
TABLE 272 SOUTH KOREA: KEY MACROINDICATORS 255
TABLE 273 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 255
TABLE 274 SOUTH KOREA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 275 SOUTH KOREA: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 256
TABLE 276 SOUTH KOREA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 277 SOUTH KOREA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 278 SOUTH KOREA: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 257
TABLE 279 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 257
TABLE 280 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 258
TABLE 281 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 258
TABLE 282 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 258
TABLE 283 SOUTH KOREA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 284 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 259
TABLE 285 REST OF ASIA PACIFIC: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 286 REST OF ASIA PACIFIC: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 260
TABLE 287 REST OF ASIA PACIFIC: PERIPHERAL VASCULAR ACCESS DEVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 260
TABLE 288 REST OF ASIA PACIFIC: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 261
TABLE 289 REST OF ASIA PACIFIC: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 261
TABLE 290 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET,
BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 261
TABLE 291 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 262
TABLE 292 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 293 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 262
TABLE 294 REST OF ASIA PACIFIC: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS,
BY TYPE, 2024–2031 (USD MILLION) 263
TABLE 295 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 264
TABLE 296 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 264
TABLE 297 LATIN AMERICA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 298 LATIN AMERICA:VOLUME ANALYSIS BY CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 265
TABLE 299 LATIN AMERICA: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 300 LATIN AMERICA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 266
TABLE 301 LATIN AMERICA: VOLUME ANALYSIS BY PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (THOUSAND UNITS) 266
TABLE 302 LATIN AMERICA: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 303 LATIN AMERICA: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 267
TABLE 304 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 267
TABLE 305 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 268
TABLE 306 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 307 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 268
TABLE 308 LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE, 2024–2031 (USD MILLION) 269
TABLE 309 BRAZIL: KEY MACROINDICATORS 270
TABLE 310 BRAZIL: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 311 BRAZIL: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 270
TABLE 312 BRAZIL: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 313 BRAZIL: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 314 BRAZIL: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 315 BRAZIL: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 272
TABLE 316 BRAZIL: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 272
TABLE 317 BRAZIL: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 272
TABLE 318 BRAZIL: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 273
TABLE 319 BRAZIL: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 273
TABLE 320 BRAZIL: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 273
TABLE 321 MEXICO: KEY MACROINDICATORS 274
TABLE 322 MEXICO: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 275
TABLE 323 MEXICO: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 275
TABLE 324 MEXICO: IMPLANTABLE PORTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 275
TABLE 325 MEXICO: PERIPHERAL VASCULAR ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 276
TABLE 326 MEXICO: PERIPHERAL VENOUS ACCESS DEVICES MARKET, BY TYPE,
2024–2031 (USD MILLION) 276
TABLE 327 MEXICO: MIDLINE CATHETERS MARKET, BY TYPE, 2024–2031 (USD MILLION) 276
TABLE 328 MEXICO: VASCULAR ACCESS DEVICE MARKET, BY ROUTE OF INSERTION,
2024–2031 (USD MILLION) 277
TABLE 329 MEXICO: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 277
TABLE 330 MEXICO: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION,
BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 331 MEXICO: VASCULAR ACCESS DEVICE MARKET, BY END USER,
2024–2031 (USD MILLION) 278
TABLE 332 MEXICO: VASCULAR ACCESS DEVICE MARKET FOR HOSPITALS, BY TYPE,
2024–2031 (USD MILLION) 278
TABLE 333 REST OF LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY TYPE,
2024–2031 (USD MILLION) 279
TABLE 334 REST OF LATIN AMERICA: CENTRAL VENOUS ACCESS DEVICES MARKET, BY TYPE, 2024–2031 (USD MILLION) 279
TABLE 335 REST OF LATIN AMERICA: IMPLANTABLE PORTS MARKET, BY TYPE,
2024–2031 (USD MILLION) 280
TABLE 336 REST OF LATIN AMERICA: PERIPHERAL VASCULAR ACCESS DEVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 337 REST OF LATIN AMERICA: PERIPHERAL VENOUS ACCESS DEVICES MARKET,
BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 338 REST OF LATIN AMERICA: MIDLINE CATHETERS MARKET, BY TYPE,
2024–2031 (USD MILLION) 281
TABLE 339 REST OF LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET,
BY ROUTE OF INSERTION, 2024–2031 (USD MILLION) 281
TABLE 340 REST OF LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281
TABLE 341 REST OF LATIN AMERICA: VASCULAR ACCESS DEVICE MARKET FOR DRUG ADMINISTRATION, BY TYPE, 2024–2031 (USD MILLION) 282
TABLE 342 REST OF LATIN AMERICA: VASCULAR ACC